T3	total-participants 491 497	27,347
T4	eligibility 498 518	postmenopausal women
T5	age 524 538	50 to 79 years
T7	total-participants 664 670	16,608
T8	control 829 836	placebo
T9	total-participants 891 897	10,739
T11	outcome 1995 2022	invasive breast cancer risk
T12	outcome 1831 1849	breast cancer risk
T13	outcome 1631 1654	breast cancer incidence
T14	outcome 1306 1319	breast cancer
T18	outcome 1469 1494	entire intervention phase
T1	intervention 27 50	Estrogen Plus Progestin
T2	control 55 69	Estrogen Alone
T6	location 559 561	US
